PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34728570-6 2022 Enzalutamide induced the expression of DNMT3A and DNMT3B in prostate cancer cells with a potential role of p53 and pRB in this process. enzalutamide 0-12 tumor protein p53 Homo sapiens 107-110 33771885-8 2021 Implications: We identified common and reproducible genomic alterations in CTCs from AR-V7 negative mCRPC men associated with poor outcomes during enzalutamide/abiraterone treatment, including CNAs in genes linked to lineage plasticity and epigenetic signaling, DNA repair, AR, TP53/RB1, PTEN, and WNT pathways. enzalutamide 147-159 tumor protein p53 Homo sapiens 278-282 35385726-4 2022 AR blockade with enzalutamide induces (1) transcriptional silencing of TP53 and hence dedifferentiation to a hybrid epithelial and mesenchymal and stem-like state and (2) inhibition of BMP signaling, which promotes resistance to AR inhibition. enzalutamide 17-29 tumor protein p53 Homo sapiens 71-75 31587305-3 2020 Other studies have shown that knockdown of RB1 and TP53 increases the expression of neuroendocrine markers, decreases the sensitivity to enzalutamide, and increases the expression of SOX2. enzalutamide 137-149 tumor protein p53 Homo sapiens 51-55 31822380-8 2020 However, TP53 GOF mutations had a positive association with prior abiraterone/enzalutamide therapy (P = .047). enzalutamide 78-90 tumor protein p53 Homo sapiens 9-13 31587305-4 2020 Importantly, knockdown of SOX2 in the context of RB1 and TP53 depletion restored sensitivity to enzalutamide and reduced the expression of neuroendocrine markers. enzalutamide 96-108 tumor protein p53 Homo sapiens 57-61 31046065-0 2019 Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer. enzalutamide 61-73 tumor protein p53 Homo sapiens 77-81 31297844-12 2019 Our data, therefore, suggest that enzalutamide"s high efficacy is at least partially independent of AR and p53 protein expression, which are frequently lost in advanced PC. enzalutamide 34-46 tumor protein p53 Homo sapiens 107-110 29302046-0 2018 p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. enzalutamide 80-92 tumor protein p53 Homo sapiens 0-3 30209161-0 2019 TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer. enzalutamide 78-90 tumor protein p53 Homo sapiens 0-4 28228262-4 2017 Combination treatment with the AR signaling inhibitor enzalutamide (ENZ) and the Chk1/2 inhibitor AZD7762 demonstrates synergy with regard to inhibition of AR-CDC6-ATR-Chk1 signaling, ATM phosphorylation induction, and apoptosis in VCaP (mutant p53) and LNCaP-C4-2b (wild-type p53) cells. enzalutamide 54-66 tumor protein p53 Homo sapiens 245-248 28228262-4 2017 Combination treatment with the AR signaling inhibitor enzalutamide (ENZ) and the Chk1/2 inhibitor AZD7762 demonstrates synergy with regard to inhibition of AR-CDC6-ATR-Chk1 signaling, ATM phosphorylation induction, and apoptosis in VCaP (mutant p53) and LNCaP-C4-2b (wild-type p53) cells. enzalutamide 54-66 tumor protein p53 Homo sapiens 277-280